This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients accrued
Patients with multiple myeloma
Number of approved sites
M1000 Biobank participants
See where and when MRDR presentations are happening in Blood 2024!
Read morePlease join us for breakfast at the MRDR Annual Breakfast Meeting at Blood 2024, 28th October
Read moreAn MRDR paper on the development and validation of a discrete-event simulation model of MM disease outcomes has now been published!
Read moreAn MRDR paper investigating variation in immunoglobulin use and survival in myeloma has now been published!
Read more
